Avalo Therapeutics AVTX Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Avalo Therapeutics’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's payments of stock issuance costs?
- Avalo Therapeutics (AVTX) reported payments of stock issuance costs of $115.5K in Q4 2025.
- What does payments of stock issuance costs mean?
- Represents the direct costs incurred by the company to raise capital through equity offerings, such as underwriting fees, legal expenses, and registration costs. These outflows reduce the net proceeds received from stock issuances and reflect the friction costs of accessing capital markets. Monitoring these costs helps investors assess the efficiency of the company's equity financing activities.